Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

The high-profile obesity and diabetes products Wegovy and Ozempic, from Danish healthcare company Novo Nordisk, will see a significant global development on Friday — as a patent on its active ...

With 90% of prescriptions in the US filled for generic drugs, there is growing concern that supplies of the medications could be in short supply due to the ongoing situation in the Strait of Hormuz, a ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

At Dr. David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments. But recently, another word is coming up just as often — generics. "It is a ...

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

In a shot in the arm for India’s high-growth weight-loss medicines market, generic versions of Danish drugmaker Novo Nordisk’s blockbuster drug semaglutide will hit the shelves on Saturday, with price ...